Added to YB: 2025-08-11
Pitch date: 2025-08-07
NVO [bullish]
Novo Nordisk A/S
-22.43%
current return
Author Info
No bio for this author
Company Info
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products.
Market Cap
DKK 1.1T
Pitch Price
DKK 305.41
Price Target
N/A
Dividend
4.94%
EV/EBITDA
7.46
P/E
10.29
EV/Sales
3.74
Sector
Pharmaceuticals
Category
value
Novo Nordisk: A High-Margin Compounder Hiding in Plain Sight
NVO: Established diabetes/GLP-1 leader with 25yr expertise in complex protein chemistry. Trading at 12-14x earnings vs LLY's 60x. Transparent operations, ethical trials reporting, foundation owns 28% ensuring stability. Proven ability to innovate past patent expiries like insulin. Obesity/diabetes market large enough for duopoly with LLY.
Read full article (2 min)